The American Journal of Medicine
Volume 110, Issue 5 , Pages 339-346 , 1 April 2001

Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors

  • Stella M Davies, MB, BS, PhD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • Corresponding Author InformationRequests for reprints should be addressed to S. M. Davies, MB, BS, PhD, MMC 422 Mayo, University of Minnesota, Minneapolis, Minnesota 55455
    • ,
  • Todd E DeFor, MS

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Phillip B McGlave, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Jeffrey S Miller, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Catherine M Verfaillie, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • John E Wagner, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Daniel J Weisdorf, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA

Received 27 July 2000 ,Accepted 19 December 2000.

References 

  1. Goldman JM, Apperley JF, Jones L, et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202–207
  2. Thomas ED, Clift RA, Fefer A, et al.  Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155–163
  3. Thomas ED, Clift RA. Indications for marrow transplantation in chronic myelogenous leukemia. Blood. 1989;73:861–864
  4. Perkins HA, Hansen JA. The U.S. National Marrow Donor Program. Am J Ped Hematol Oncol. 1994;16:30–34
  5. Confer DL. Unrelated donor marrow registries. Curr Opin Hematol. 1997;4:408–412
  6. Kernan NA, Bartsch G, Ash RC, et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602
  7. Davies SM, Ramsay NKC, Haake RJ, et al.  Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant. 1994;13:51–57
  8. Ochs L, Shu XO, Miller J, et al.  Late infections after allogeneic bone marrow transplantations (comparison of incidence in related and unrelated donor transplant recipients). Blood. 1995;86:3979–3986
  9. Hehlmann R, Heimpel H, Hasford J, et al.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064–4077
  10. Italian Cooperative Study Group in Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  11. Hasford J, Baccarani M, Hehlmann R, et al.  Interferon-alpha, and hydroxyurea in early chronic myeloid leukemia. A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood. 1996;87:5384–5391
  12. Chronic Myeloid Leukemia Trialists’ Collaborative Group . Interferon alpha versus chemotherapy for chronic myeloid leukemia (a meta-analysis of seven randomized trials). J Natl Cancer Inst. 1997;89:1616–1620
  13. Ohnishi K, Tomonaga M, Kamada N, et al.  A long-term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res. 1998;22:779–786
  14. Kantarjian HM, Smith TL, O’Brien S, et al.  Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254–261
  15. Allen NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha for chronic myeloid leukaemia (improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia). Lancet. 1995;345:1392–1397
  16. Giralt SA, Kantarjian HM, Talpaz M, et al.  Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055–1061
  17. Beelen DW, Graeven U, Elmaagacli AH, et al.  Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981–2990
  18. Morton AJ, Gooley T, Hansen JA, et al.  Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394–401
  19. Davies SM, Shu XO, Blazar BR, et al.  Unrelated donor bone marrow transplantation (influence of HLA A and B incompatibility on outcome). Blood. 1995;86:1636–1642
  20. Filipovich AH, Vallera DA, Youle RJ, et al.  Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation. 1997;44:62–69
  21. Wagner JE, Santos GW, Noga SJ, et al.  Bone marrow graft engineering by counterflow centrifugal elutriation (results of a phase I-II clinical trial). Blood. 1990;75:1370–1377
  22. Snedecor G, Cochran W. Statistical Methods, 8th ed. Ames, IA: Iowa State University Press, 1989.
  23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  24. Cox DR. Regression models and life tables. J Roy Stat Soc B. 1972;34:187–220
  25. Hansen JA, Gooley TA, Martin PJ, et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968
  26. Dini G, Lamparelli T, Rondelli R, et al.  Unrelated donor marrow transplantation for chronic myelogenous leukaemia. Br J Haematol. 1998;102:544–552
  27. Enright H, Daniels K, Arthur DC, et al.  Related donor marrow transplant for chronic myeloid leukemia (patient characteristics predictive of outcome). Bone Marrow Transplant. 1996;17:537–542
  28. Appelbaum FR, Clift R, Radich J, Anasetti C, Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol. 1995;22:405–411
  29. Hessner MJ, Endean DJ, Casper JT, et al.  Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell–depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995;86:3987–3996
  30. Kurtzberg J, Laughlin M, Graham ML, et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157–166
  31. Lee SJ, Kuntz KM, Horowitz MM, et al.  Unrelated donor bone marrow transplantation for chronic myelogenous leukemia (a decision analysis). Ann Intern Med. 1997;127:1080–1088
  32. Druker BJ, Talpaz M, Resta D, et al.  Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood. 1999;94:368A
  33. Talpaz M, Silver RT, Druker B, et al.  A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. Blood. 2000;96:469A
  34. Kantarjian H, Sawyers C, Hochhaus A, et al.  Phase II study of STI 57I, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). Blood. 2000;96:470A

☆ Supported in part by Grant CA65493 from the National Institutes of Health, Bethesda, Maryland, and by the Children’s Cancer Research Fund and Bone Marrow Transplant Fund.

PII: S0002-9343(01)00629-5

The American Journal of Medicine
Volume 110, Issue 5 , Pages 339-346 , 1 April 2001

Article Tools

* Image Usage & Resolution